The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Abstract
Using a simple model of ligand-receptor interactions, the interactions between ligands and receptors of varying complexities are studied and the probabilities of binding calculated. It is observed that as the systems become more complex the chance of observing a useful interaction for a randomly chosen ligand falls dramatically. The implications of this for the design of combinatorial libraries is explored. A large set of drug leads and optimized compounds is profiled using several different properties relevant to molecular recognition. The changes observed for these properties during the drug optimization phase support the hypothesis that less complex molecules are more common starting points for the discovery of drugs. An extreme example of the use of simple molecules for directed screening against thrombin is provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bissantz, C., Folkers, G., & Rognan, D. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001044l · Cited by 740
A Scoring Scheme for Discriminating between Drugs and Nondrugs
Sadowski, J., & Kubinyi, H. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9706776 · Cited by 392
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
The role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Twenty years on: the impact of fragments on drug discovery
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000
Key Topics in Molecular Docking for Drug Design
Torres, P. H. M., Sodero, A. C. R., Jofily, P., & Silva-Jr, F. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184574 · Cited by 641
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Adding calorimetric data to decision making in lead discovery: a hot tip
Ladbury, J. E., Klebe, G., & Freire, E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3054 · Cited by 398
Drug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Cooper, T. W. J., Campbell, I. B., & Macdonald, S. J. F. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002238 · Cited by 299
Ursu, O., Rayan, A., Goldblum, A., & Oprea, T. I. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.52 · Cited by 276
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Ligand efficiency and fragment-based drug discovery
Bembenek, S. D., Tounge, B. A., & Reynolds, C. H. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.007 · Cited by 196
The many roles of molecular complexity in drug discovery
Méndez-Lucio, O., & Medina-Franco, J. L. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.009 · Cited by 180
Fragment-Based Lead Discovery and Design
Joseph-McCarthy, D., Campbell, A. J., Kern, G., & Moustakas, D. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400731w · Cited by 129
Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors
Prati, F., De Simone, A., Bisignano, P., Armirotti, A., Summa, M., Pizzirani, D., Scarpelli, R., Perez, D. I., Andrisano, V., Perez‐Castillo, A., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410456 · Cited by 128
Prati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110
Badapple: promiscuity patterns from noisy evidence
Yang, J. J., Ursu, O., Lipinski, C. A., Sklar, L. A., Oprea, T. I., & Bologa, C. G. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0137-3 · Cited by 103
Neumann, L., Ritscher, A., Müller, G., & Hafenbradl, D. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9288-x · Cited by 20
Early ADME/T Predictions: Toy or Tool?
Tetko, I. V., & Oprea, T. I. (2008) · Chemoinformatics Approaches to Virtual Screening · doi:10.1039/9781847558879-00240 · Cited by 5
Metadata
- Authors
- Hann, M. M., Leach, A. R., & Harper, G.
- Venue
- Journal of Chemical Information and Computer Sciences
- Publisher
- American Chemical Society (ACS)
- Published
- 2001-04-27
- Volume
- 41
- Issue
- 3
- Pages
- 856-864
- ISSN
- 0095-2338 (ISSN-L)
- OpenAlex
- W2047710091
- Cited by
- 877
- References
- 2
- FWCI
- 29.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
